Tempest Therapeutics Enters Agreement With Roche To Advance Evaluation Of Amezalpat Combination Therapy
Tempest Therapeutics Enters Agreement With Roche To Advance Evaluation Of Amezalpat Combination Therapy
Tempest Therapeutics與羅氏達成協議,推進Amezalpat聯合療法評估
Under the agreement, Roche will supply atezolizumab globally and Tempest will sponsor and lead the pivotal study. This agreement builds on a clinical collaboration between the companies pursuant to which amezalpat was combined with atezolizumab and bevacizumab in first-line HCC patients and compared to atezolizumab and bevacizumab alone in a randomized Phase 1b/2 study. Tempest retains all development and commercial rights to amezalpat.
根據協議,羅氏將在全球範圍內提供atezolizumab,而Tempest將贊助並領導關鍵研究。該協議是基於兩家公司之間的臨床合作,根據該合作,amezalpat與atezolizumab和bevacizumab在一線HCC患者中結合,並與atezolizumab和bevacizumab單獨在隨機分組的第1b/2期研究中進行比較。Tempest保留amezalpat的所有開發和商業權利。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。